(4-cyano-phenylamino)-(5-ethoxy-2-fluoro-3-hydroxy-phenyl)-acetic acid ethyl ester | 376601-44-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4-cyano-phenylamino)-(5-ethoxy-2-fluoro-3-hydroxy-phenyl)-acetic acid ethyl ester
• 英文别名: (RS)-(4-cyano-phenylamino)-(5-ethoxy-2-fluoro-3-hydroxy-phenyl)-acetic acid ethyl ester；ethyl 2-(4-cyanoanilino)-2-(5-ethoxy-2-fluoro-3-hydroxyphenyl)acetate
• CAS: 376601-44-4
• 化学式: C₁₉H₁₉FN₂O₄
• 分子量: 358.369
• InChiKey: QBKJFSAUPRFYJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  91.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (4-cyano-phenylamino)-(5-ethoxy-2-fluoro-3-hydroxy-phenyl)-acetic acid ethyl ester 在 盐酸 、 lithium hydroxide 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 乙醇 、 氯仿 为溶剂， 反应 7.25h， 生成 (R)-(4-carbamimidoyl-phenylamino)-[5-ethoxy-2-fluoro-3-[(R)-tetrahydro-furan-3-yloxy]-phenyl]-acetic acid
  参考文献：
  名称：

  Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

  摘要：

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.042
• 作为产物：
  描述：

  4-氟苯乙醚 在 咪唑 、 正丁基锂 、 五甲基二乙烯三胺 、 三氟化硼乙醚 、 水 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 (4-cyano-phenylamino)-(5-ethoxy-2-fluoro-3-hydroxy-phenyl)-acetic acid ethyl ester
  参考文献：
  名称：

  Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

  摘要：

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.03.042

文献信息

• N-(4-carbamimidoyl-phenyl)-glycine derivatives
  申请人：——

  公开号：US20020004608A1

  公开（公告）日：2002-01-10

  N-(4-carbamimidoyl-phenyl)-glycine derivatives have the formula: 1 wherein X and R 1 to R 5 are as defined herein, and includes hydrates or solvates and/or physiologically acceptable salts thereof and/or physiologically acceptable esters thereof.

  N-(4-羰基苄基)-甘氨酸衍生物的化学式为： 其中X和R1至R5如本文所定义，并包括其水合物或溶剂合物和/或其生理上可接受的盐和/或其生理上可接受的酯。
• [EN] PHENYLGLYCINE DERIVATIVES<br/>[FR] DERIVES DE PHENYLGLYCINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001090051A1

  公开（公告）日：2001-11-29

  The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula (I) wherein X and R1 to R5 are as defined in the description and in the claims, as well as hydrates or solvates and/or physiologically acceptable salts thereof and/or physiologically acceptable esters thereof.

  本发明涉及公式（I）中的新型N-（4-氨基甲酰基苯基）-甘氨酸衍生物，其中X和R1到R5如说明书和权利要求中所定义，以及其水合物或溶剂化物和/或生理上可接受的盐和/或生理上可接受的酯。
• N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES
  申请人：——

  公开号：US20030166683A1

  公开（公告）日：2003-09-04

  The invention is concerned with water soluble N—(4-carbamimidoyl-phenyl)-glycine derivatives of formula (I) 1 wherein R 1 to R 4 and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor and can be used as medicaments.

  本发明涉及水溶性的公式(I)1中的N-(4-氨基甲酰基苯基)甘氨酸衍生物，其中R1至R4和n如说明和权利要求中所定义，以及其生理上可接受的盐。这些化合物能抑制由因子VIIa和组织因子诱导的凝血因子Xa、IXa和凝血酶的形成，可用作药物。
• PHENYLGLYCINE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1289939A1

  公开（公告）日：2003-03-12
• WATER SOLUBLE PHENYLGLYCINE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1474391A1

  公开（公告）日：2004-11-10